WebJul 15, 2024 · On June 7, 2024, the FDA granted accelerated approval to aducanumab (brand name Aduhelm), the first drug in 18 years for Alzheimer’s disease. Since then the FDA has modified the original language of the approval to recommend that it only be used in certain patients with mild cognitive impairment or early Alzheimer's disease. Web2 hours ago · A meeting of the U.S. FDA's Peripheral and Central Nervous System Drugs Advisory Committee is scheduled for June 9, 2024. This FDA Committee's digital …
A new peptide may hold potential as an Alzheimer’s treatment
WebJun 7, 2024 · Matt York/AP. The Food and Drug Administration approved the drug aducanumab to treat patients with Alzheimer's disease on Monday. It is the first new drug approved by the agency for Alzheimer's ... Alzheimer's causes chronic, low-level brain cell inflammation. Researchers are studying ways to treat inflammatory processes at work in Alzheimer's disease. The drug sargramostim (Leukine) is currently in research. It's thought that the drug may stimulate the immune system to protect the brain from harmful … See more Some of the new Alzheimer's treatments in development target microscopic clumps of the protein beta-amyloid (plaques). Plaques are a … See more Researchers are studying the effects of insulin on the brain and brain cell function, and insulin changes in the brain that may be related to Alzheimer's. A trial testing an insulin nasal spray determined that the drug wasn't effective … See more A vital brain cell transport system collapses when a protein called tau twists into microscopic fibers called tangles, which are another common brain abnormality of … See more Growing evidence suggests that brain health is closely linked to heart and blood vessel health. The risk of developing dementia appears to increase as a result of many conditions that damage the heart or arteries. These … See more our system was down
A new peptide may hold potential as an Alzheimer
WebMar 17, 2024 · Aducanumab and Lecanemab for Alzheimer's Both drugs attempt to slow the cognitive decline of people with Alzheimer's. How aducanumab works Aducanumab is a monoclonal antibody therapy that's... WebApr 5, 2024 · Current approaches to treating Alzheimer’s focus on helping people maintain mental function, treating the underlying disease process, and managing behavioral symptoms. Medications to maintain mental … Web2 days ago · With further testing, the researchers hope that the peptide could eventually be used as a treatment for patients with Alzheimer's disease and other forms of dementia that have CDK5 overactivation. rogue company cmg